Mega-Trends Portfolio: an undervalued major?
One analyst has said that it is "the most undervalued major in global pharma." Another commentator enthused that one of its drugs could be a holy grail, and it looks likely that another of its drugs is on the verge of becoming the most popular in the world. Find out more about this exciting constituent of our Mega-Trends portfolio.
It is not often you come across a solid dividend-paying company with considerable growth potential, but 130 year-old Merck & Co (US:MRK), a constituent of our high-performing Mega-Trends Portfolio, could be one such a company.
In 2020, the Investor’s Champion Mega-Trends Portfolio returned 76%. That’s twice the return of the S&P 500 technology index and more than 4-times the performance of the S&P 500 as a whole. The mega-trends portfolio has also materially outperformed…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article Next article
